- 16 нояб. 2017 г.
IPHARMA clinical trial results were represented at the XXI Russian Oncology Congress
On November 14-16, XXI Russian Oncology Congress passed in Moscow. It is one of the largest international events in the field of oncology, in which more than 5,000 doctors take part annually. Permanent organizers of the congress: N.N. Blokhin Russian Cancer Research Center and the Russian Society of Clinical Oncology under the aegis of the Russian Oncology Association. The following issues discussed in this year: National Cancer Control Program. How will Russian oncology bene
- 12 мая 2016 г.
IPHARMA was authorized by the Ministry of Healthcare to conduct the Phase II clinical study of Quisi
On May 5th, 2016, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product Quisinostat. Protocol № ONC-14-NSCLCII-1-1QUI-3 "Multicenter double-blind randomized placebo-controlled Phase II clinical study with the combination of Gemcitabine, Cisplatin and Quisinostat versus Gemcitabine, Cisplatin and placebo in 1st line treatment of patients with advanced Stage IIIb-IV squamous NSCLC". The stu